查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018443

神經血管器材市場：按產品類型、適應症、最終用戶和通路分類的全球市場預測，2026-2032年

Neurovascular Devices Market by Product Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經血管器械市場價值將達到 55.9 億美元，到 2026 年將成長至 60.1 億美元，到 2032 年將達到 93.3 億美元，複合年成長率為 7.57%。

主要市場統計數據
基準年 2025 55.9億美元
預計年份：2026年 60.1億美元
預測年份 2032 93.3億美元
複合年成長率 (%) 7.57%

對神經血管設備生態系統進行清晰的管理概述，使臨床創新與商業性和監管決策標準保持一致。

神經血管器械領域正處於快速臨床創新與醫療系統監管日益加強的交匯點，這要求經營團隊在策略選擇上做出清晰的決策。器械設計、與影像技術的融合以及術前術後護理的進步，重新定義了臨床醫生的期望，並拓展了適應症。同時，保險公司和採購負責人也越來越重視可驗證的療效和成本效益。相關人員現在需要簡潔明了、基於證據的總結，將技術能力與臨床終點和商業性可行性聯繫起來。

技術成熟度、監管預期和程序標準化如何重塑採用路徑和競爭優勢？

神經血管器械市場格局正經歷一場變革，其驅動力主要來自三大面向：技術成熟、流程標準化、支付方期望的轉變。醫療設備的改進越來越依賴真實世界的性能數據和計算模型，加速了從一次性原型產品向臨床穩定平台的轉變。精細化的流程和標準化的培訓路徑正在降低患者預後的差異性，並將應用範圍從專科轉診中心擴展到更廣泛的醫療機構。

重組採購和定價策略：近期關稅措施對供應鏈、採購和夥伴關係的累積影響。

近期關稅措施和貿易政策調整給神經血管器械供應鏈帶來了明顯的壓力，製造商和供應商必須應對這些壓力。影響原料、零件和成品進口的關稅推高了部分製造商的採購成本，促使他們更加重視國內生產和策略採購。為此，一些製造商正在重新審視與供應商的契約，並探索近岸外包和區域性製造地，以維持利潤率並確保供應的連續性。

詳細的細分分析揭示了產品架構、臨床適應症、醫療保健環境和通路如何驅動不同的採用和購買行為。

神經血管器械領域的細分分析揭示了獨特的市場推廣路徑以及與商業性效用。在血流導引裝置方面，諸如Pipeline栓塞平台、絲狀結構和Surpass架構系統等裝置在輸送和血管壁黏附性方面展開競爭。同時，微導管依靠親水塗層和聚四氟乙烯（PTFE）塗層來最佳化其在彎曲腦血管內的導航性能。彈簧圈技術涵蓋從裸金屬到生物活性和水凝膠增強型等多種類型，旨在提高動脈瘤閉塞的持久性。支架分為編織型和雷射切割型，以平衡徑向強度、柔軟性和血管貼合性。

決定全球主要醫療保健地區差異化商業策略的跨區域監管、報銷和生產趨勢。

區域趨勢對神經血管器械產業的監管路徑、報銷框架和生產策略有顯著影響，美洲、歐洲、中東和非洲以及亞太地區之間存在顯著差異。在美洲，醫院系統的整合以及對真實世界數據的重視正在影響報銷討論，並提升衛生經濟學在採購談判中的重要性。該地區的醫療機構通常優先考慮那些能夠提高手術效率並縮短住院時間的技術，這反過來又會影響商業性訊息和臨床試驗設計。

產品差異化、策略聯盟和卓越營運如何塑造競爭優勢和長期臨床醫生偏好。

神經血管器材領域的競爭格局圍繞著產品差異化、實證醫學證據的累積以及旨在拓展核心技術臨床效用的策略聯盟。成熟的器械製造商通常利用其豐富的產品系列，提供包含器械、影像軟體和培訓服務的整合解決方案，從而降低醫院系統採用整合解決方案的門檻。相較之下，專業公司和Start-Ups通常專注於有限的創新方向，例如新型血流旁路支架或先進的線圈化學技術，透過建立臨床驗證點來吸引合作夥伴和收購者的興趣。

為醫療設備製造商和供應商提供實用策略指南，以協調臨床證據、製造韌性和客製化商業化，從而加速部署。

產業領導企業應採取多管齊下的策略，將研發重點與可證實的臨床價值結合，同時增強價值鏈的韌性和商業性靈活性。首先，應優先進行臨床證據項目，以解答支付方和醫院決策者關於療效和成本抵銷的問題，確保研究終點與實際決策標準相符。其次，將資料收集和分析功能整合到醫療器材和上市後註冊系統中，以持續產生效能洞察，從而支援報銷討論和產品迭代改進。

採用嚴謹的混合方法研究途徑，結合專家訪談、監管分析和臨床證據整合，為策略決策提供支援。

本報告的研究結合了對臨床專業人員、採購經理和醫療設備公司高階主管的定性訪談，以及對監管指南和同行評審臨床文獻的系統分析。主要訪談對象包括介入神經神經科、神經介入放射科醫生、醫院採購經理和產品開發經理，揭示了公開資訊來源中未一致的營運實際情況和決策因素。調查團隊將訪談結果與監管申報文件、醫療設備附加檔和臨床註冊結果進行交叉比對，以檢驗觀察到的趨勢並檢驗新出現的推廣障礙。

透過協調創新、證據生成和營運韌性，簡潔地整合策略挑戰，以確保永續的臨床部署。

本分析的整體結果清楚地表明，相關人員需要迅速採取謹慎行動。器械設計和手術流程的技術進步正在拓展臨床選擇，但這些技術的成功應用將取決於可證實的療效、價格透明度和供應可靠性。監管機構的期望和支付方的審查日益凸顯了整合證據策略和上市後資料收集的重要性，而貿易政策的轉變則進一步強化了多元化採購和區域製造策略的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 神經血管器材市場：依產品類型分類

  • 栓塞裝置
    • 線圈栓塞裝置
    • 液體栓塞系統
    • 血流灌注支架
  • 血管成形術和支架置入系統
  • 神經血栓除去裝置
    • 血栓摘取支架
    • 吸力裝置
  • 支援和存取設備
    • 微導管
    • 導管導引線
    • 球囊導管

第9章：神經血管器材市場：依適應症分類

  • 腦動脈瘤
  • 缺血性中風
  • 動靜脈畸形（AVM）和瘻管
  • 頸動脈和顱內動脈狹窄
  • 出血性中風

第10章 神經血管器材市場：依最終用戶分類

  • 門診手術中心
    • 醫院相關設施
    • 獨立設施
  • 醫院
  • 專科診所
  • 研究機構和學術機構

第11章：神經血管器材市場：依通路分類

  • 直銷
  • 線上銷售
  • 第三方經銷商

第12章 神經血管器材市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 神經血管器材市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 神經血管器材市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國：神經血管器材市場

第16章 中國：神經血管器械市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Stryker Corporation
  • Medtronic plc
  • Johnson & Johnson
  • Penumbra, Inc.
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • ASAHI INTECC CO., LTD.
  • Kaneka Corporation
  • BALT Group
  • Acandis GmbH
  • Phenox GmbH
  • Integer Holdings Corporation
  • Imperative Care, Inc.
  • Rapid Medical Ltd.
  • Anaconda Biomed SL
  • ArtVentive Medical Group, Inc.
  • Endologix Inc.
  • Evasc Medical Systems Corp
  • iVascular SLU
  • Koninklijke Philips NV
  • Lepu Medical Technology（Beijing）Co.,Ltd.
  • Medical Murray, Inc.
  • NeuroVasc Technologies Inc.
  • Nventric, Inc.
  • Scientia Vascular, Inc.
  • Secant Group, LLC
  • Vesalio, LLC
  • Zeus Company LLC
  • ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
Product Code: MRR-0360AB17E1FE

The Neurovascular Devices Market was valued at USD 5.59 billion in 2025 and is projected to grow to USD 6.01 billion in 2026, with a CAGR of 7.57%, reaching USD 9.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.59 billion
Estimated Year [2026] USD 6.01 billion
Forecast Year [2032] USD 9.33 billion
CAGR (%) 7.57%

A clear executive overview of the neurovascular devices ecosystem that aligns clinical innovation with commercial and regulatory decision criteria

The neurovascular devices domain sits at the intersection of rapid clinical innovation and heightened health system scrutiny, demanding clarity for executives making strategic choices. Advances in device design, imaging integration, and periprocedural care have reshaped clinician expectations and broadened procedural indications, while payers and procurement officers increasingly demand demonstrable outcomes and cost-effectiveness. Stakeholders now require concise, evidence-based syntheses that link technological capabilities to clinical endpoints and commercial viability.

Clinical momentum around minimally invasive approaches and imaging-guided interventions has raised the bar for device performance and operator training. Concurrently, healthcare providers face pressure to optimize patient throughput and justify capital and consumable expenditures through measurable improvements in morbidity and length of stay. Investors and corporate strategists are therefore looking for analyses that translate procedural innovation into sustainable adoption pathways. This introduction frames the broader report by aligning clinical, regulatory, and commercial vectors that will determine which technologies and providers gain enduring traction in the neurovascular ecosystem.

Throughout the subsequent sections, the report zeroes in on the major drivers of change, the segmentation patterns that influence procurement and reimbursement decisions, and the regional and competitive dynamics that shape market entry and expansion. The aim is to provide leadership teams with a coherent narrative that guides prioritization and investment decisions in a complex, fast-evolving field.

How technological maturation, regulatory expectations, and procedural standardization are reshaping adoption pathways and competitive advantages

The landscape for neurovascular devices is experiencing transformative shifts driven by three converging forces: technological maturation, procedural standardization, and shifting payer expectations. Device iterations are increasingly informed by real-world performance data and computational modeling, which in turn accelerate the transition from single-use prototypes to clinically robust platforms. Procedural refinements and standardized training pathways are reducing variability in patient outcomes, pushing adoption from niche referral centers toward broader institutional settings.

Regulatory authorities are also evolving their expectations for clinical evidence and post-market surveillance, prompting manufacturers to embed data-generation capabilities into device lifecycles. This regulatory pressure is catalyzing partnerships between device makers and imaging or software vendors, as stakeholders seek integrated solutions that offer measurable outcome improvements and streamlined workflows. In addition, supply chain resilience and manufacturing scalability have become strategic priorities; leaders are investing in reagent sourcing strategies and dual-sourcing to mitigate external shocks.

The cumulative effect is a marketplace where differentiation increasingly rests on clinical evidence, procedural efficiency, and the capacity to demonstrate value to payers and hospital procurement committees. These shifts have practical implications for product development roadmaps, commercialization models, and collaboration strategies, and they necessitate that companies recalibrate R&D priorities and market entry timing to align with both clinical practice patterns and reimbursement realities.

The cumulative supply chain, procurement, and partnership implications of recent tariff activity that are reshaping sourcing and pricing strategies

Recent tariff measures and trade policy adjustments have created discernible pressure points across the neurovascular devices supply chain that manufacturers and providers must navigate. Tariffs influencing raw material imports, componentry, and finished devices have raised procurement costs for some manufacturers and incentivized onshore manufacturing and strategic sourcing arrangements. In response, several manufacturers have re-evaluated supplier contracts and explored nearshoring and regional manufacturing hubs to preserve margin integrity and supply continuity.

For hospitals and ambulatory centers, the pass-through effects of increased procurement costs have pressured capital allocation decisions and brought greater scrutiny to device utilization and cost-per-case metrics. As a result, purchasing departments are intensifying competitive bidding and lengthening vendor qualification cycles, while clinical teams are being asked to justify device selection through evidence demonstrating improved clinical outcomes or reduced downstream costs. At the same time, tariffs have heightened the importance of flexible distribution channels; organizations are diversifying between direct sales, third-party distributors, and digital procurement platforms to retain negotiating leverage.

Importantly, the policy environment has also influenced strategic partnerships and licensing arrangements. Firms with manufacturing footprints outside tariff-impacted jurisdictions have gained relative logistical advantages, while others have accelerated transfer agreements and regional licensing to maintain market access. Moving forward, stakeholders who proactively optimize sourcing, adapt pricing strategies, and strengthen regional logistics will be better positioned to absorb policy-induced cost variability and sustain supply reliability.

In-depth segmentation analysis revealing how product architectures, clinical indications, care settings, and distribution routes drive distinct adoption and procurement behaviors

Segmentation within the neurovascular devices space reveals distinct pathways to adoption and distinct commercial imperatives tied to product type, clinical indication, end user, and distribution channel. Product typology spans flow diversion devices, microcatheters, neurovascular coils, and neurovascular stents, each carrying unique engineering constraints and clinical utility. Within flow diversion, devices like pipeline embolization platforms, silk-style constructs, and surpass-architecture systems compete on deliverability and wall apposition, while microcatheters rely on coatings such as hydrophilic and PTFE to optimize navigation through tortuous cerebral vasculature. Coil technologies range from bare metal to bioactive and hydrogel-enhanced variants that aim to improve aneurysm occlusion durability. Stent families, divided between braided and laser-cut architectures, balance radial strength against flexibility and vessel conformability.

Clinical indication segmentation further differentiates adoption dynamics across arteriovenous malformation interventions, intracranial aneurysm treatments, intracranial stenosis management, and ischemic stroke therapies. AVM interventions pivot on the selection of glue embolic agents versus Onyx-based systems, whereas intracranial aneurysm care involves choices among endovascular coiling, flow diversion strategies, and stent-assisted coiling, with device selection influenced by aneurysm morphology and clinical risk profiles. Intracranial stenosis care leans on balloon angioplasty and stenting techniques, and ischemic stroke pathways include intraarterial thrombolysis and mechanical thrombectomy systems, each demanding specific device compatibilities and imaging workflows.

End-user segmentation highlights differentiated purchasing behaviors across ambulatory surgical centers, hospitals, and specialty clinics. Ambulatory centers vary by affiliation status, hospitals range from primary community facilities to tertiary care centers with complex neurointerventional programs, and specialty clinics encompass interventional radiology and neurology clinics that may act as referral hubs. Distribution channels also cast significant influence on market access and service models, with direct sales supported by field representatives and institutional contracts, online sales through e-commerce platforms and manufacturer web portals, and third-party distributors spanning retail and wholesale networks. Navigating this layered segmentation requires tailored value propositions for each stakeholder, aligning device features with procedural requirements, reimbursement realities, and procurement models.

Cross-regional regulatory, reimbursement, and manufacturing dynamics that determine differentiated commercial strategies across major global healthcare regions

Regional dynamics exert a powerful influence on regulatory pathways, reimbursement frameworks, and manufacturing strategies across the neurovascular devices landscape, with material differences observable between the Americas, Europe, Middle East & Africa, and Asia-Pacific jurisdictions. In the Americas, consolidation in hospital systems and a strong emphasis on real-world evidence are shaping reimbursement discussions and elevating the importance of health economics in procurement conversations. Providers in this region often prioritize technologies that demonstrate procedural efficiency and the potential to reduce length of stay, which in turn affects commercial messaging and clinical trial design.

In Europe, Middle East & Africa, regulatory harmonization efforts and variable reimbursement environments create both opportunities and complexities. Manufacturers must navigate a mosaic of national health systems and payer requirements, while also capitalizing on centralized procurement opportunities for cross-border tenders. Meanwhile, the Asia-Pacific region presents a mix of rapidly expanding procedural volumes and differing regulatory maturation, prompting strategies that balance cost competitiveness with scalable clinical education programs. Localization of manufacturing and targeted clinical partnerships have become common tactics in the region to accelerate adoption while addressing pricing sensitivity.

Across all regions, cross-border logistics, intellectual property considerations, and regional training capabilities inform both entry strategies and partnership models. Stakeholders that invest early in region-specific regulatory planning, localized clinical evidence generation, and supply chain redundancy tend to secure more reliable market access and foster deeper clinician engagement, thereby improving the odds of sustained adoption across geographically diverse healthcare ecosystems.

How product differentiation, strategic alliances, and operational excellence are shaping competitive advantage and long-term clinician preference

Competitive dynamics among companies active in the neurovascular devices sector center on product differentiation, evidence generation, and strategic collaborations that extend the clinical utility of core technologies. Established device manufacturers often leverage broad portfolios to offer bundled solutions that include devices, imaging software, and training services, thereby lowering the barrier to adoption for hospital systems seeking integrated offerings. In contrast, specialized firms and startups typically focus on narrow innovation vectors-such as novel flow diversion scaffolds or advanced coil chemistries-to establish clinical proof points and attract partnership or acquisition interest.

Strategic transactions, licensing agreements, and co-development partnerships are prominent routes to scale technology and accelerate market entry, particularly where regulatory or clinical validation timelines are lengthy. Companies that align with leading neurointerventional centers to co-design procedural workflows gain early adopters and real-world data streams that support payer discussions. Similarly, alliances with imaging and software vendors enable device makers to incorporate analytics and outcome tracking into their value proposition.

Operational excellence remains a differentiator; firms that invest in manufacturing quality systems, robust post-market surveillance, and responsive field support tend to sustain clinician trust and institutional contracts. Pricing flexibility, bundled contracting, and outcomes-based agreements are increasingly employed by companies to address procurement complexity and to demonstrate commitment to shared patient outcome goals. Ultimately, the firms that combine technical differentiation with clear pathways to evidence generation and dependable service delivery will be best positioned to capture long-term clinical preference.

A pragmatic strategic playbook for device makers and providers to align clinical evidence, manufacturing resilience, and tailored commercialization to accelerate adoption

Industry leaders should adopt a multi-pronged strategy that aligns R&D priorities with demonstrable clinical value, while simultaneously reinforcing supply chain resilience and commercial agility. First, prioritize clinical evidence programs that are designed to answer payer and hospital decision-maker questions about outcomes and cost offsets, ensuring that study endpoints map to real-world decision criteria. Second, embed data capture and analytics capabilities into devices and post-market registries to generate ongoing performance insights that support reimbursement discussions and iterative product improvements.

Third, diversify manufacturing and procurement footprints to mitigate policy or logistic disruptions, and consider regional partnerships or licensing to preserve market continuity. Fourth, tailor go-to-market approaches to end-user segmentation by creating differentiated value propositions for ambulatory centers, tertiary hospitals, and specialty clinics that reflect each setting's clinical workflows and purchasing constraints. Fifth, expand commercial models to include flexible contracting, bundled offerings, and training partnerships that reduce adoption friction and align incentives between providers and manufacturers.

Finally, invest in collaborative relationships with imaging and software providers, clinical leaders, and distribution partners to create comprehensive procedural solutions. By coupling targeted clinical programs with resilient operations and adaptive commercialization, organizations can both accelerate adoption and demonstrate long-term value to stakeholders across the neurovascular ecosystem.

A rigorous mixed-methods research approach combining expert interviews, regulatory analysis, and clinical evidence synthesis to support strategic decision-making

The research underpinning this report synthesizes primary qualitative engagement with clinical experts, procurement leaders, and device executives alongside systematic analysis of regulatory guidance and peer-reviewed clinical literature. Primary interviews were conducted with interventional neurologists, neurointerventional radiologists, hospital purchasing managers, and product development leaders to surface operational realities and decision drivers that do not consistently appear in published sources. The research team triangulated interview findings with regulatory filings, device labeling information, and clinical registry outcomes to validate observed trends and to identify emerging adoption barriers.

Secondary research included a structured review of clinical trials, systematic reviews, and health technology assessment reports to establish the clinical context for device usage across indications. Supply chain analysis drew on publicly available trade data, manufacturing footprints, and corporate disclosures to map likely tariff and sourcing exposure points. In addition, the methodology incorporated scenario planning to examine how supply chain, reimbursement, and regulatory permutations could affect procurement dynamics, without projecting specific market sizes or forecasts.

Throughout, the methodology emphasized reproducibility and transparency. Interview protocols and inclusion criteria were standardized, and data sources were cross-referenced to reduce bias. The combination of qualitative insight and document-based verification yields a robust evidence base designed to inform strategy and operational planning for stakeholders engaged in the neurovascular devices domain.

A concise synthesis of strategic imperatives that align innovation, evidence generation, and operational resilience to secure durable clinical adoption

The cumulative insights presented across this analysis paint a clear imperative for stakeholders to act with both speed and deliberation. Technological progress in device design and procedural practice is expanding clinical options, but adoption will hinge on demonstrable outcomes, pricing clarity, and supply reliability. Regulatory expectations and payer scrutiny are elevating the importance of integrated evidence strategies and post-market data capture, while trade policy shifts are reinforcing the value of diversified sourcing and regional manufacturing strategies.

For decision-makers, the path forward requires aligning product development with the information needs of clinicians, payers, and hospital purchasers. This means prioritizing clinical programs that generate actionable outcomes data, designing commercial models that reduce procurement friction, and investing in service capabilities that support training and device lifecycle management. Organizations that combine technical differentiation with operational resilience and evidence-driven commercialization will create durable advantages and clearer pathways to clinical preference.

In sum, the neurovascular devices landscape presents significant opportunity, but realizing that opportunity demands coordinated strategies across R&D, regulatory planning, manufacturing, and go-to-market execution. Stakeholders who act now to shore up evidence generation, supply chain flexibility, and tailored commercial engagement will be best positioned to translate innovation into sustained clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Devices Market, by Product Type

  • 8.1. Embolization Devices
    • 8.1.1. Coil Embolization Devices
    • 8.1.2. Liquid Embolic Systems
    • 8.1.3. Flow Diversion Stents
  • 8.2. Angioplasty & Stenting Systems
  • 8.3. Neurothrombectomy Devices
    • 8.3.1. Stent Retrievers
    • 8.3.2. Aspiration/Suction Devices
  • 8.4. Support & Access Devices
    • 8.4.1. Microcatheters
    • 8.4.2. Guidewires
    • 8.4.3. Balloon Catheters

9. Neurovascular Devices Market, by Indication

  • 9.1. Cerebral Aneurysms
  • 9.2. Ischemic Stroke
  • 9.3. Arteriovenous Malformations (AVMs) & Fistulas
  • 9.4. Carotid Artery & Intracranial Stenosis
  • 9.5. Hemorrhagic Stroke

10. Neurovascular Devices Market, by End User

  • 10.1. Ambulatory Surgical Centers
    • 10.1.1. Hospital Affiliated Centers
    • 10.1.2. Independent Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics
  • 10.4. Research Laboratories & Academic Institutions

11. Neurovascular Devices Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Online Sales
  • 11.3. Third Party Distributors

12. Neurovascular Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurovascular Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurovascular Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Neurovascular Devices Market

16. China Neurovascular Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Stryker Corporation
  • 17.6. Medtronic plc
  • 17.7. Johnson & Johnson
  • 17.8. Penumbra, Inc.
  • 17.9. Terumo Corporation
  • 17.10. MicroPort Scientific Corporation
  • 17.11. ASAHI INTECC CO., LTD.
  • 17.12. Kaneka Corporation
  • 17.13. BALT Group
  • 17.14. Acandis GmbH
  • 17.15. Phenox GmbH
  • 17.16. Integer Holdings Corporation
  • 17.17. Imperative Care, Inc.
  • 17.18. Rapid Medical Ltd.
  • 17.19. Anaconda Biomed S.L.
  • 17.20. ArtVentive Medical Group, Inc.
  • 17.21. Endologix Inc.
  • 17.22. Evasc Medical Systems Corp
  • 17.23. iVascular S.L.U.
  • 17.24. Koninklijke Philips N.V.
  • 17.25. Lepu Medical Technology(Beijing)Co.,Ltd.
  • 17.26. Medical Murray, Inc.
  • 17.27. NeuroVasc Technologies Inc.
  • 17.28. Nventric, Inc.
  • 17.29. Scientia Vascular, Inc.
  • 17.30. Secant Group, LLC
  • 17.31. Vesalio, LLC
  • 17.32. Zeus Company LLC
  • 17.33. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROVASCULAR DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LIQUID EMBOLIC SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LIQUID EMBOLIC SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LIQUID EMBOLIC SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ANGIOPLASTY & STENTING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ANGIOPLASTY & STENTING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ANGIOPLASTY & STENTING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ASPIRATION/SUCTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ASPIRATION/SUCTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ASPIRATION/SUCTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CEREBRAL ANEURYSMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CEREBRAL ANEURYSMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CEREBRAL ANEURYSMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS (AVMS) & FISTULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS (AVMS) & FISTULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS (AVMS) & FISTULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CAROTID ARTERY & INTRACRANIAL STENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CAROTID ARTERY & INTRACRANIAL STENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CAROTID ARTERY & INTRACRANIAL STENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 175. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 203. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 210. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 212. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)